Jedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, talks about the phase III CheckMate 067 trial.
Jedd Wolchok, MD, PhD
Articles by Jedd Wolchok, MD, PhD
Latest Updated Articles
Dr. Jedd Wolchok Talks About the Phase III CheckMate 067 Trial and its Effects on Untreated Melanoma PatientsPublished: November 3rd 2015 | Updated: